60 related articles for article (PubMed ID: 19661035)
1. What's PARPing up for triple-negative breast cancer?
Sledge GW
Clin Breast Cancer; 2009 Aug; 9(3):139. PubMed ID: 19661035
[No Abstract] [Full Text] [Related]
2. PARP inhibition in breast cancer.
Garber J
Clin Adv Hematol Oncol; 2009 Sep; 7(9):573-5. PubMed ID: 20020667
[No Abstract] [Full Text] [Related]
3. [Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer].
Hashimoto K; Tamura K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1187-91. PubMed ID: 20647696
[TBL] [Abstract][Full Text] [Related]
4. An Achilles' heel for breast cancer?
Caldecott KW; Chalmers A
Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
[No Abstract] [Full Text] [Related]
5. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
6. Foreword. Poly(ADP-ribose) polymerase inhibitors in clinical development.
Kummar S
Curr Probl Cancer; 2011; 35(1):6. PubMed ID: 21300206
[No Abstract] [Full Text] [Related]
7. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
Stebbing J; Ellis P; Tutt A
Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
[No Abstract] [Full Text] [Related]
8. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
9. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh MW; Loman N; Scott C; Friedlander M; Kaufman B; Garber JE; Tutt A; Robson ME
J Clin Oncol; 2011 Nov; 29(32):4224-6. PubMed ID: 21931031
[No Abstract] [Full Text] [Related]
10. PARP inhibitors: will the new class of drugs match the hype?
Tuma RS
J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
[No Abstract] [Full Text] [Related]
11. PARP inhibitors.
Plummer R
Clin Adv Hematol Oncol; 2012 May; 10(5):322-3. PubMed ID: 22706542
[No Abstract] [Full Text] [Related]
12. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
13. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
14. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
15. In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time?
Dent RA; Bristow RG
J Clin Oncol; 2011 Jun; 29(16):2130-2. PubMed ID: 21519017
[No Abstract] [Full Text] [Related]
16. [DNA repair pathway and molecularly targeted therapy for malignant tumors].
Tamura K
Rinsho Ketsueki; 2012 Apr; 53(4):409-16. PubMed ID: 22687974
[No Abstract] [Full Text] [Related]
17. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
18. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
19. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2010; 15 Suppl 5():39-48. PubMed ID: 21138954
[TBL] [Abstract][Full Text] [Related]
20. Molecular oncology: The positive in the negative.
Powell K
Nature; 2012 May; 485(7400):S52-3. PubMed ID: 22648498
[No Abstract] [Full Text] [Related]
[Next] [New Search]
